Novocure
NVCR | NASDAQ
$11.30
-$0.53 (-4.48%)
At close: Nov 16, 2026, 4:00 PM ET
$11.26
-$0.04 (-0.35%)
After-hours:
Nov 16, 2026, 7:43 PM ET
Novocure Company Profile
Company profile explainedCompany Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Key Executives
| Name | Position |
|---|---|
| Frank Leonard | Chief Executive Officer & Director |
| Christoph Brackmann | Chief Financial Officer |
| Mukund Paravasthu | Chief Operating Officer |
| Adam Daney | Head of Investor Relations |
| Barak Ben Arye | General Counsel |
| Michael Puri | Chief Human Resources Officer |
| Uri Weinberg | Chief Innovation Officer & Chief Medical Officer |
| William F. Doyle | Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | S-8 | Filing |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 09, 2026 | 8-K | Current Report |
| Sep 01, 2026 | 8-K | Current Report |
| Jul 23, 2026 | 8-K | Current Report |
| Jul 23, 2026 | 10-Q | Quarterly Report |
| Jul 01, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
Novocure
| Country | Switzerland |
| IPO Date | Oct 2, 2015 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 1,605 |
| CEO | Frank Leonard |
Stock Details
| Ticker Symbol | NVCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645113 |
| CUSIP Number | G6674U108 |
| ISIN Number | JE00BYSS4X48 |
| SIC Code | 3841 |
Recent News
- 3 days ago / businesswire.comJAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer
- 6 days ago / fool.comFDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
- 8 days ago / businesswire.comNovocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
- 15 days ago / zacks.comDon't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
- 15 days ago / fool.comNovoCure: 3 Key Takeaways for Long-Term Investors
- 18 days ago / seekingalpha.comNovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript
- 18 days ago / marketbeat.comNovoCure Q3 Earnings Call Highlights
- 19 days ago / zacks.comNovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
- 20 days ago / businesswire.comNovocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
- 1 month ago / seekingalpha.comNovocure: A Mispriced Cash-Generating Biotech With Upside Potential
Add to Watchlist
Select watchlists to add or remove NVCR